Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive COVID-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for COVID-19.
Description: Number and type of adverse events
Measure: Adverse events outcomes without attribution Time: Baseline, until 30 days after last doseDescription: Number and type of adverse events
Measure: Adverse events attributable Time: Baseline, until 30 days after last doseDescription: Disease severity as measured by 7 point ordinal scale
Measure: Clinical improvement Time: Baseline, until 30 days after last doseDescription: Type of oxygen support treatment
Measure: Levels of treatment Time: Baseline, until 30 days after last doseDescription: Change from Baseline of d-Dimer
Measure: d-Dimer Time: Baseline, until 30 days after last doseDescription: Change from Baseline of CRP
Measure: C Reactive Protein Time: Baseline, until 30 days after last doseDescription: Change from Baseline of Ferritin
Measure: Ferritin Time: Baseline, until 30 days after last doseDescription: Change from Baseline of Lactate dehydrogenase
Measure: Lactate dehydrogenase Time: Baseline, until 30 days after last doseDescription: Change from Baseline of A1c
Measure: A1c Time: Baseline, until 30 days after last dose